HENDERSON, Nev., July 9, 2024
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)
("Volition"), a multi-national epigenetics company, has appointed
PharmaVentures Ltd ("PharmaVentures"), a leading transaction
advisory firm, to provide strategic advice and transactional
support on the out-license of Volition's expanding oncology
portfolio.
PharmaVentures has been engaged to act as an advisor to Volition
to help secure licensing deals with industry leaders for both Nu.Q®
Cancer – a range of simple blood-based assays to help detect, guide
treatment, and monitor cancer, and Capture-PCR™ – a novel detection
method for liquid biopsy in cancer and potentially other
diseases.
Gael Forterre, Chief Commercial Officer, Volition, said:
"PharmaVentures is a respected, international advisory company
with a proven track record in licensing, partnering, and strategic
alliances. PharmaVentures' specialist experience in deal-making and
extensive network means that it is ideally placed to support us as
we seek to commercialize our potentially ground-breaking oncology
and Capture PCR™ portfolio.
"We have a large amount of study data that we anticipate is
close to being ready for inclusion in our data rooms and look
forward to negotiating our first licensing deal in the human
space."
Adrian Dawkes, Managing Director,
PharmaVentures, said:
"We believe Volition's cutting-edge, epigenetic technology has
the potential to significantly improve patient outcomes in the
diagnosis and management of cancer patients and other diseases. Our
role is to secure major licensing deals with key industry players
and ensure Volition's low-cost, simple blood tests are accessible
worldwide. We are delighted to be supporting Volition in fulfilling
its mission."
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases in both humans and animals. For more information about
Volition's technology go to: www.volition.com
About Volition
Volition is a multi-national company focused on advancing the
science of epigenetics. Volition is dedicated to saving lives and
improving outcomes for people and animals with life-altering
diseases through earlier detection, as well as disease and
treatment monitoring.
Through its subsidiaries, Volition is developing and
commercializing simple, easy to use, cost-effective blood tests to
help diagnose and monitor a range of diseases, including some
cancers and diseases associated with NETosis, such as sepsis. Early
diagnosis and monitoring have the potential not only to prolong the
life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's and PharmaVentures' website
addresses are not incorporated by reference into this document and
should not be considered part of this document. Such website
addresses are included in this document as inactive textual
references only.
About PharmaVentures
PharmaVentures Ltd is a premier life science transaction
advisory firm and a leading international company in partnering,
M&A deals and strategic alliances. Founded by
Fintan Walton over 30 years ago,
PharmaVentures has acted as advisor on over 1,000 deal related
projects covering licensing, mergers, acquisitions, divestments,
and joint venture activities for companies worldwide.
PharmaVentures' deep bank of specialist experience, deal
analytics and network of contacts from innovators to large pharma
makes us uniquely placed to support business in all aspects of deal
making and strategic planning. PharmaVentures is well known for its
deep insight into deal structures and its success for generating
partnering interest.
PharmaVentures' services include: M&A, Licensing,
Fundraising support, Strategy, Valuations, Pricing & Market
Access.
NOTE: PharmaVentures Limited, wholly owned subsidiary
PharmaVentures Capital Limited is authorised and regulated by the
Financial Conduct Authority.
For more details, visit https://www.pharmaventures.com.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's expectations related to the
timing, completion, success and delivery of data from clinical
studies, the effectiveness and availability of Volition's
blood-based diagnostic, prognostic and disease monitoring tests,
Volition's ability to develop and successfully commercialize such
test platforms for early detection of cancer and other diseases as
well as serving as a diagnostic, prognostic or disease monitoring
tools for such diseases, and Volition's success in securing
licensing and/or distribution agreements with third parties for its
products. Volition's actual results may differ materially from
those indicated in these forward-looking statements due to numerous
risks and uncertainties, including, without limitation, results of
studies testing the efficacy of its tests. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products; a failure by
the marketplace to accept the products in Volition's development
pipeline or any other diagnostic, prognostic or disease monitoring
products Volition might develop; Volition's failure to secure
adequate intellectual property protection; Volition will face
fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring market and its rapid technological change;
downturns in domestic and foreign economies; and other risks,
including those identified in Volition's most recent Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q, as well as other
documents that Volition files with the Securities and Exchange
Commission. These statements are based on current expectations,
estimates and projections about Volition's business based, in part,
on assumptions made by management. These statements are not
guarantees of future performance and involve risks, uncertainties
and assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this press release, and,
except as required by law, Volition does not undertake an
obligation to update its forward-looking statements to reflect
future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos
are trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original
content:https://www.prnewswire.com/news-releases/volition-appoints-pharmaventures-for-capture-pcr-and-oncology-portfolio-licensing-302191829.html
SOURCE VolitionRx Limited